drugset / Trial / NCT03617484
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.
Timeline
- Start
- 2020-07
- Primary completion
- 2023-01
- Completion
- 2030-07
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |